Held by 2 specialist biotech funds
# Signal Note: Deerfield Management Initiates MASI Position Deerfield's $2.1M entry into Masimo signals confidence in the noninvasive monitoring platform's expansion beyond traditional hospital settings, likely driven by recent FDA clearances in consumer/remote patient monitoring or upcoming revenue inflection from existing hospital automation contracts. Flynn's healthcare multi-strategy mandate suggests conviction around near-term commercial execution rather than speculative pipeline bets, pointing to near-term visibility on revenue or margin expansion.